Abstract
Snail2 has an important role in the epithelial-mesenchymal transition (EMT) and tumor metastasis. Here, we report that Snail2 is highly expressed during TGF-β induced EMT in HL-7702 cells. Additionally, overexpression of Snail2 successfully promotes the migration and invasion of these cells, both in vitro and in a mouse model. Furthermore, our results show that HDAC1 and HDAC3 could suppress the Snail2 gene promoter. Moreover, we find that the acetylation of H3K4 and H3K56 are significantly reduced during the EMT process of liver HL-7702 cells. Thus, our results indicate that HDAC1 and HDAC3 epigenetically suppress the expression of Snail2 during the EMT of liver cells, revealing an opposing function of HDACs during the migration of malignant tumors.
Introduction
Hepatocellular carcinoma (HCC) is characterized by high rates of recurrence and metastasis, making it one of the most challenging cancers to treat. A pivotal stage in the metastatic cascade is the epithelial-mesenchymal transition (EMT), a biological process where stationary epithelial cells transform into migratory mesenchymal cells. While transcription factors such as Snail, ZEB, and Twist are known to orchestrate this transition, the epigenetic mechanisms that regulate these "master switches" are still being elucidated. This study focuses on the role of Histone Deacetylases (HDACs) and their unexpected function as inhibitors of Snail2-mediated EMT in liver cells.
Methods
Researchers utilized the HL-7702 human liver cell line, inducing EMT with TGF-β1 (10 ng/ml) over 12 days. The study employed a variety of techniques to dissect the regulatory pathways:
- Genetic Manipulation: Lentiviral vectors were used for stable gene overexpression, while siRNA was used for the transient knockdown of Snail2, HDAC1, and HDAC3.
- Functional Assays: Cell migration and invasion were quantified using wound healing and transwell assays.
- Epigenetic Analysis: Luciferase reporter assays measured Snail2 promoter activity, and Chromatin Immunoprecipitation (ChIP) was used to determine the acetylation status of histones H3K4 and H3K56 at the Snail2 promoter.
- In Vivo Validation: A BALB/c nude mouse model was used to track liver metastasis of GFP-labeled cells.
Results
Snail2 is the Primary Driver of TGF-β1-Induced EMT
Among various EMT-related transcription factors, Snail2 was found to be the most significantly upregulated during TGF-β1-induced transition in HL-7702 cells. The induction of EMT was marked by the loss of the epithelial marker E-cadherin and the concomitant increase in mesenchymal markers such as N-cadherin, Vimentin, and Fibronectin. Crucially, knockdown of Snail2 was sufficient to reverse these molecular changes.
Snail2 Promotes Migration and Metastatic Potential
Functional assays confirmed that Snail2 expression is essential for the increased motility of liver cells during EMT. Silencing Snail2 led to a significant reduction in the migration rate of TGF-β1-treated cells. Furthermore, in vivo experiments demonstrated that Snail2 overexpression significantly increased the incidence of liver metastasis and tissue necrosis in mouse models.
HDAC1 and HDAC3 Epigenetically Repress Snail2
A key finding of this study is that HDAC1 and HDAC3 directly suppress the Snail2 promoter. During EMT, the levels of acetylated H3K4 and H3K56 at the Snail2 promoter are reduced, leading to gene repression. Overexpression of these HDACs inhibited cell migration, while treatment with the HDAC inhibitor Mocetinostat increased Snail2 expression and restored migratory capacity. This suggests that HDAC1 and HDAC3 act as epigenetic "brakes" on the metastatic process in this context.
Discussion
This research highlights a complex and somewhat counterintuitive role for HDACs in cancer. While often associated with promoting tumor progression, HDAC1 and HDAC3 appear to inhibit metastasis in liver cells by silencing Snail2. This discovery underscores the need for caution in the clinical use of HDAC inhibitors, as these drugs might inadvertently promote EMT and metastasis in specific cancer types by relieving the epigenetic suppression of key transcription factors. Future studies are needed to determine if these findings translate to human HCC patients and to identify which patients might benefit most—or least—from HDAC-targeted therapies.
Summary updated